Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Mirati Therapeutics (MRTX) stocks in Canada

Learn how to easily invest in Mirati Therapeutics stocks.

Mirati Therapeutics is a biotechnology business based in the US. Mirati Therapeutics stocks (MRTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $163.51 – an increase of 1.74% over the previous week. Mirati Therapeutics employs 199 staff and has a trailing 12-month revenue of around $73.5 million.

How to buy shares in Mirati Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MRTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Mirati Therapeutics stock price (NASDAQ:MRTX)

Use our graph to track the performance of MRTX stocks over time.

Mirati Therapeutics shares at a glance

Information last updated 2022-01-18.
Latest market close$120.81
52-week range$115.57 - $225.47
50-day moving average $141.02
200-day moving average $157.43
Wall St. target price$220.08
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-9.54

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Mirati Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Mirati Therapeutics price performance over time

Historical closes compared with the close of $120.81 from 2022-01-19

1 week (2022-01-13) 1.74%
1 month (2021-12-17) -16.66%
3 months (2021-10-20) -31.47%
6 months (2021-07-20) -26.13%
1 year (2021-01-20) -43.23%
2 years (2020-01-17) 24.48%
3 years (2019-01-18) 86.09%
5 years (2017-01-20) 2,201.14%

Mirati Therapeutics financials

Revenue TTM $73.5 million
Gross profit TTM $13.4 million
Return on assets TTM -32.19%
Return on equity TTM -59.11%
Profit margin 0%
Book value $20.94
Market capitalisation $6.9 billion

TTM: trailing 12 months

Mirati Therapeutics share dividends

We're not expecting Mirati Therapeutics to pay a dividend over the next 12 months.

Have Mirati Therapeutics's shares ever split?

Mirati Therapeutics's shares were split on a 1:50 basis on 2 July 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Mirati Therapeutics shares – just the quantity. However, indirectly, the new 4900% higher share price could have impacted the market appetite for Mirati Therapeutics shares which in turn could have impacted Mirati Therapeutics's share price.

Mirati Therapeutics share price volatility

Over the last 12 months, Mirati Therapeutics's shares have ranged in value from as little as $115.57 up to $225.465. A popular way to gauge a stock's volatility is its "beta".

MRTX.US volatility(beta: 1.33)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mirati Therapeutics's is 1.3259. This would suggest that Mirati Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Mirati Therapeutics overview

Mirati Therapeutics, Inc. , a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Stocks similar to Mirati Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site